1. China Stocks

  2. •

    Health technology

  3. •

    Medical specialties
PW Medtech Group Ltd.

PW Medtech Group Ltd.

HHKEX:1358
0.88
HKD
-0.03
(-3.31%)
1.90BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.37
0.36
0.31
0.2
0.18
0.2
0.23
0.16
0.17
0.34
0.43
0.5
0.55
- -
Basic EPS, GAAP
0.06
0.11
0.12
0.12
0.08
1.06
0.05
0.4
0.47
0.07
0.1
0.1
0.06
- -
Free Cash Flow per Basic Share
-0.04
-0.06
- -
-0.01
-0.05
-0.02
0.03
0.04
0.02
0.13
0.08
0.16
0.09
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
1.31
- -
0.05
0.09
0.09
- -
Book Value per Share
1.14
1.26
1.37
1.47
1.76
2.86
2.94
3.26
2.42
2.52
2.58
2.67
2.68
2.68
Tangible Book Value per Share
0.93
0.63
0.76
0.9
1.61
2.73
2.82
3.14
2.31
1.46
1.52
1.57
1.61
1.61
Basic Weighted Avg Shares
1,248
1,670
1,675
1,625
1,576
1,569
1,569
1,569
1,569
1,566
1,566
1,543
1,511
1,470
Sales/Revenue/Turnover
457
608
516
320
287
311
362
247
271
537
675
769
824
- -
Operating Margin (%)
25.93
34.73
46.41
36.67
15.54
19.61
6.23
-16.74
8.02
12.75
24.09
18.08
12.39
- -
Depreciation Expense
21
39
60
63
46
21
29
28
31
79
98
118
140
- -
Net Income, GAAP
78
177
209
195
122
1,666
82
632
739
106
153
151
94
- -
Effective Tax Rate (%)
20.08
16.42
16.77
15.81
25.07
8.74
4.47
- -
- -
18.31
11.27
16.2
18.03
- -
Profit Margin (%)
17.04
29.05
40.46
61
42.55
535.89
22.64
255.43
272.34
19.75
22.69
19.61
11.46
- -
Working Capital
1,307
687
636
791
1,856
-286
-319
3,948
2,489
1,778
1,882
1,917
2,144
2,144
LT Debt
- -
- -
- -
- -
- -
- -
- -
18
- -
1
- -
10
5
5
Total Equity
1,899
2,111
2,299
2,334
2,944
4,494
4,608
5,108
3,792
4,638
4,825
4,803
4,854
4,854
Return on Invested Capital (%)
7.4
8.54
8.9
4.48
1.27
0.72
0.03
- -
- -
2.36
3.49
3.11
2.06
- -
Return on Capital (%)
5.41
9.09
9.35
8.48
3.52
41.79
2.16
- -
- -
1.98
2.14
2.27
1.12
- -
Return on Common Equity (%)
6.93
8.81
9.46
8.42
4.79
45.92
1.8
13
16.61
2.74
3.83
3.76
2.38
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
2
1
17
LT Borrowings
6
15
- -
LT Finance Leases
5
4
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,487
1,487
1,472
Market Capitalization
1,397
1,791
1,706

Working Capital

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
2,094
2,401
2,361
Cash, Cash Equivalents & STI
1,687
1,778
1,808
Accounts Receivable, Net
73
83
67
Inventories
120
130
145
Total Current Liabilities
177
249
217
Payables & Accruals
- -
- -
- -
ST Debt
2
1
17
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.49%
0.23%
1.05%
Free Cash Flow
102.05%
129%
-44.93%
Net Income, GAAP
173.28%
-12.64%
-37.41%
Sales/Revenue/Turnover
9.92%
30.85%
7.1%
Total Cash Common Dividend
- -
- -
-2.99%

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
675
2024
- -
- -
769
2025
- -
- -
824

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.1
2024
- -
- -
0.1
2025
- -
- -
0.06

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.05
2024
- -
- -
0.09
2025
- -
- -
0.09

Company Description

Company Profile APIChatGPT
CEO
Yue E Zhang
Full Time Employees
1,477
Sector
Health technology
Industry
Medical specialties
Address
Building 1 Beijing BE China 101204
IPO Date
Nov 8, 2013
Website
pwmedtech.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
PW Medtech Group Limited is a leading investment holding medical device company focused on research, development, manufacturing, and sales of advanced medical consumables in China and internationally, including markets in India, the Americas, Africa, and other regions. Founded in 1997 and headquartered in Beijing, People's Republic of China, the company operates through three core segments: Infusion Set Business, offering non-PVC-based infusion sets, precision filter infusion sets, light-resistant infusion sets, intravenous cannula products, insulin needles and pens; Blood Purification Business, providing hemodialysis and blood purification devices such as high flux hemodialyzers, low flux hemodialyzers, hemodiafilters, hemoperfutors, and dialysis machines; and Regenerative Medical Biomaterials Business, specializing in animal-derived regenerative medical biomaterials and human tissue repair alternative products like artificial dura mater for neurosurgery. The company maintains leading market positions in precision filter and non-PVC infusion sets in China, supported by an extensive distribution network across 31 provinces, municipalities, and cities, strong R&D capabilities, and high-tech subsidiaries including those focused on orthopedic implants historically. Recent developments include ongoing share repurchase programs, with cumulative repurchases of approximately 78.9 million shares as of December 31, 2024, representing 5.04% of issued shares, and a voluntary suspension of the review process for the subsequent listing of subsidiary Sichuan Ruijian; the company also announced an increased interim dividend of CNY0.053 per share for the six months ended June 30, 2025, payable in December 2025, alongside solid earnings growth and strategic focus on high-value medical consumables expansion.